CLINICAL_TRIALS
trial_result
· 2013-06-24
Clinical Trial Update: ZD 1839 in Treating Patients With Metastatic Kidney Cancer [Phase 2]
Summary
A Phase 2 trial evaluating ZD 1839 (gefitinib) in patients with metastatic kidney cancer has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED